Thomas R. Müller

Thomas R. Müller

Auto-generated profile, based on publicly available information

Thomas R. Müller

Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2019 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
KSKilian Schober
Kilian Schober
TMThomas R. Müller
Thomas R. Müller
FGFüsun Gökmen
Füsun Gökmen
SGSimon Grassmann
Simon Grassmann
MEManuel Effenberger
Manuel Effenberger
DBDirk H Busch
Dirk H Busch

16 March 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
KSKilian Schober
Kilian Schober
FVFlorian Voit
Florian Voit
SGSimon Grassmann
Simon Grassmann
TMThomas R. Müller
Thomas R. Müller
JEJoel Eggert
Joel Eggert
DBDirk H Busch
Dirk H Busch

6 September 2024 in Science Immunology
Verified
Journal Article
Closed access
TKTobias Kammann
Tobias Kammann
CCCurtis Cai
Curtis Cai
TSTakuya Sekine
Takuya Sekine
EMElli Mouchtaridi
Elli Mouchtaridi
CBCaroline Boulouis
Caroline Boulouis
JSJohan Sandberg
Johan Sandberg
Mucosal-associated invariant T (MAIT) cells are unconventional T cells that recognize microbial riboflavin pathway metabolites presented by evolutionarily conserved MR1 molecules. We explored the human MAIT cell compartment across organ donor–matched blood, barrier, and lymphoid tissues. MAIT cell population size was donor dependent with distinct tissue compartmentalization patterns and adaptations: Intestinal CD103 + resident MAIT cells presented an immunoregulatory CD39 high CD27 low profile, whereas MAIT cells expressing NCAM1/CD56 dominated in the liver and exhibited enhanced effector capacity with elevated response magnitude and polyfunctionality. Both intestinal CD39 high and hepatic CD56 + adaptations accumulated with donor age. CD56 + MAIT cells displayed limited T cell receptor–repertoire breadth, elevated MR1 binding, and a transcriptional profile skewed toward innate activation pathways. Furthermore, CD56 was dynamically up-regulated to a persistent steady-state equilibrium after exposure to antigen or IL-7. In summary, we demonstrate functional heterogeneity and tissue site adaptation in resident MAIT cells across human barrier tissues with distinct regulatory and effector signatures.

12 July 2023 in Science Translational Medicine
Verified
Journal Article
Open access
TMThomas R. Müller
Thomas R. Müller
TSTakuya Sekine
Takuya Sekine
DTDarya Trubach
Darya Trubach
JNJulia Niessl
Julia Niessl
PCPuran Chen
Puran Chen
MBMarcus Buggert
Marcus Buggert
Suboptimal immunity to SARS-CoV-2 mRNA vaccination has frequently been observed in individuals with various immunodeficiencies. Given the increased antibody evasion properties of emerging SARS-CoV-2 subvariants, it is necessary to assess whether other components of adaptive immunity generate resilient and protective responses against infection. We assessed T cell responses in 279 individuals, covering five different immunodeficiencies and healthy controls, before and after booster mRNA vaccination, as well as after Omicron infection in a subset of patients. We observed robust and persistent Omicron-reactive T cell responses that increased markedly upon booster vaccination and correlated directly with antibody titers across all patient groups. Poor vaccination responsiveness in immunocompromised or elderly individuals was effectively counteracted by the administration of additional vaccine doses. Functionally, Omicron-reactive T cell responses exhibited a pronounced cytotoxic profile and signs of longevity, characterized by CD45RA + effector memory subpopulations with stem cell–like properties and increased proliferative capacity. Regardless of underlying immunodeficiency, booster-vaccinated and Omicron-infected individuals appeared protected against severe disease and exhibited enhanced and diversified T cell responses against conserved and Omicron-specific epitopes. Our findings indicate that T cells retain the ability to generate highly functional responses against newly emerging variants, even after repeated antigen exposure and a robust immunological imprint from ancestral SARS-CoV-2 mRNA vaccination.

1 January 2020 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
TMThomas R Müller
Thomas R Müller
CSCorinna Schuler
Corinna Schuler
MHMonika Hammel
Monika Hammel
AKAmelie Köhler
Amelie Köhler
SJSabrina Jutz
Sabrina Jutz
PSPeter Steinberger
Peter Steinberger
Objective: Transgenic re‐expression enables unbiased investigation of T‐cell receptor (TCR)‐intrinsic characteristics detached from its original cellular context. Recent advancements in TCR repertoire sequencing and development of protocols for direct cloning of full TCRαβ constructs now facilitate large‐scale transgenic TCR re‐expression. Together, this offers unprecedented opportunities for the screening of TCRs for basic research as well as clinical use. However, the functional characterisation of re‐expressed TCRs is still a complicated and laborious matter. Here, we propose a Jurkat‐based triple parameter TCR signalling reporter endogenous TCR knockout cellular platform (TPRKO) that offers an unbiased, easy read‐out of TCR functionality and facilitates high‐throughput screening approaches.Methods: As a proof‐of‐concept, we transgenically re‐expressed 59 human cytomegalovirus‐specific TCRs and systematically investigated and compared TCR function in TPRKO cells versus primary human T cells.Results: We demonstrate that the TPRKO cell line facilitates antigen‐HLA specificity screening via sensitive peptide‐MHC‐multimer staining, which was highly comparable to primary T cells. Also, TCR functional avidity in TPRKO cells was strongly correlating to primary T cells, especially in the absence of CD8αβ co‐receptor.Conclusion: Overall, our data show that the TPRKO cell lines can serve as a surrogate of primary human T cells for standardised and high‐throughput investigation of TCR biology.

1 June 2020 in Cells
Verified
Journal Article
Open access
PDF file
KSKilian Schober
Kilian Schober
TMThomas R. Müller
Thomas R. Müller
DBDirk H Busch
Dirk H Busch
Natural adaptive immunity co-evolved with pathogens over millions of years, and adoptive transfer of non-engineered T cells to fight infections or cancer so far exhibits an exceptionally safe and functional therapeutic profile in clinical trials. However, the personalized nature of therapies using virus-specific T cells, donor lymphocyte infusion, or tumor-infiltrating lymphocytes makes implementation in routine clinical care difficult. In principle, genetic engineering can be used to make T-cell therapies more broadly applicable, but so far it significantly alters the physiology of cells. We recently demonstrated that orthotopic T-cell receptor (TCR) replacement (OTR) by clustered regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9) can be used to generate engineered T cells with preservation of near-physiological function. In this review, we present the current status of OTR technology development and discuss its potential for TCR-based therapies. By providing the means to combine the therapeutic efficacy and safety profile of physiological T cells with the versatility of cell engineering, OTR can serve as an “enabler” for TCR-based therapies.